Speaker illustration

Doctor David Fitchett

St. Michael's Hospital, Toronto (Canada)

Member of:

European Society of Cardiology

Modern management of diabetes in cardiology: impact of SGLT2 inhibition on cardiovascular outcomes and heart failure (EBAC Accredited)

Event: ESC CONGRESS 2017

Topic: Drug therapy

Session type: Satellite Symposium

Thumbnail

SGLT2 inhibition in diabetes and heart failure: discuss the evidence

Event: ESC CONGRESS 2016

Topic: Diabetes management

Session type: EBAC Accredited Educational Programme - Experts on the Spot

Thumbnail

SGLT2 inhibition, diabetes and CVD: where does this fit in CV risk management?

Event: ESC CONGRESS 2016

Topic: Diabetes management

Session type: EBAC Accredited Educational Programme

Thumbnail

This platform is supported by

logo Novo Nordisk